Karuna Therapeutics, Inc. (KRTX) News
Filter KRTX News Items
KRTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KRTX News Highlights
- For KRTX, its 30 day story count is now at 4.
- Over the past 20 days, the trend for KRTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest KRTX News From Around the Web
Below are the latest news stories about KARUNA THERAPEUTICS INC that investors may wish to consider to help them evaluate KRTX as an investment opportunity.
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual MeetingBOSTON, May 22, 2023--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that data from the EMERGENT-1, EMERGENT-2, and EMERGENT-3 trials evaluating KarXT in schizophrenia will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held from May 30, 2023 to June 2, 2023 in Miami, Florida. A |
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q1Karuna Therapeutics (KRTX) reports encouraging first-quarter 2023 results. The company beats estimates for earnings and sales. |
Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business UpdatesBOSTON, May 04, 2023--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the first quarter of 2023 and provided a general business update. |
Karuna Therapeutics to Present at Upcoming Investor ConferencesBOSTON, May 02, 2023--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that management will present at the following upcoming investor conferences: |
3 Biotech Buyout Targets to Watch89bio (NASDAQ: ETNB), Karuna Therapeutics (NASDAQ: KRTX), and Morphic Therapeutics (NASDAQ: MORF) are clinical-stage biotech companies that make attractive buyout targets. It can also lead to cirrhosis, permanent scarring of the liver that can lead to liver cancer. |
Full Year 2023 PureTech Health PLC Earnings CallFull Year 2023 PureTech Health PLC Earnings Call |
11 Best Mid-Cap Healthcare Stocks To Buy NowIn this article, we discuss 11 best mid-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Mid-Cap Healthcare Stocks To Buy Now. The healthcare industry outlook is currently uncertain due to a combination of factors such as economic troubles, a shortage of healthcare workers, […] |
Karuna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023BOSTON, April 20, 2023--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it will host a live conference call and webcast on Thursday, May 4, 2023 at 8:00 a.m. ET to review first quarter 2023 financial results and provide a general business update. |
Karuna Therapeutics' (NASDAQ:KRTX) investors will be pleased with their splendid 165% return over the last three yearsIt might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero... |
12 Most Promising Healthcare Stocks According to AnalystsIn this article, we will take a look at the 12 most promising healthcare stocks according to analysts. To see more such companies, go directly to 5 Most Promising Healthcare Stocks According to Analysts. 2023 is turning out to be a horrific year for financial markets as investors are starting to see a glimpse of […] |